Fig. 3: Effectiveness of mRNA vaccines against symptomatic SARS-CoV-2 BA.1 and BA.2 Omicron infections.
From: Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar
Effectiveness (a) of the BNT162b2 vaccine and (b) of the mRNA-1273 vaccine. a Includes 7022 and 12,278 biologically independent samples for cases and controls, respectively, in the BA.1 analysis and 21,541 biologically independent samples for each of cases and controls in the BA.2 analysis in the BNT162b2 vaccine study. b includes 3574 and 6176 biologically independent samples for cases and controls, respectively, in the BA.1 analysis and 13,537 biologically independent samples for each of cases and controls in the BA.2 analysis in the mRNA-1273 vaccine study. Data are presented as effectiveness point estimates. Error bars indicate the corresponding 95% confidence intervals.
